• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
【24h】

A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.

机译：一项为期3年的自然主义研究，对53名接受利培酮治疗的患有广泛性发育障碍的学龄前儿童进行了研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Only sparse and short-term data are available on pharmacologic treatments in very young children with pervasive developmental disorders (PDD). The purpose of this 3-year naturalistic study (March 1999-April 2002) is to describe the clinical outcome of a consecutive sample of preschool children with PDD treated with risperidone monotherapy. METHOD: The sample consisted of 45 boys and 8 girls aged 3.6 to 6.6 years (mean +/- SD age = 4.6 +/- 0.7 years) with a DSM-IV diagnosis of autistic disorder or PDD, not otherwise specified. Outcome measures included the Children's Psychiatric Rating Scale (CPRS), Clinical Global Impressions-Improvement scale (CGI-I), Children's Global Assessment Scale (CGAS), and a checklist for risperidone side effects. RESULTS: Patients received risperidone for a period ranging from 1 to 32 months (7.9 +/- 6.8 months). Twenty-five patients (47.2%) continued to receive risperidone after the study was completed, while 28 (52.8%) discontinued due to side effects (22.6% [N = 12]), parents' choice (18.9% [N = 10]), lack of efficacy (5.7% [N = 3]), and decision of the treating psychiatrist (5.7% [N = 3]). The optimal dose was 0.55 +/- 0.2 mg/ day. Significant improvement at the last observation was found in CPRS (p < .0001) and CGAS (p < .0001) scores. On the basis of both an improvement of 25% in CPRS score and a score of 1 or 2 on the CGI-I, 46.8% (N = 22) of subjects were considered responders. Behavioral disorders and affect dysregulation were more sensitive to treatment than was interpersonal functioning. Responders received higher doses of medication for a longer period and had a greater weight gain than did nonresponders. Increased prolactin levels without clinical signs (65% [24 of 37]) and increased appetite (15% [8 of 531) were the most frequent side effects. CONCLUSION: These findings suggest that low-dose risperidone may positively affect the clinical outcome in young children with PDD not only in the short-term, but also in the long-term period.
机译：背景：只有极少的短期数据可用于非常普遍的发育性疾病（PDD）的年幼儿童的药物治疗。这项为期3年的自然主义研究（1999年3月至2002年4月）的目的是描述接受利培酮单药治疗的学龄前儿童PDD连续样本的临床结果。方法：该样本由年龄在3.6至6.6岁（平均+/- SD年龄= 4.6 +/- 0.7岁）的45名男孩和8名女孩组成，DSM-IV诊断为自闭症或PDD，未另作说明。结果指标包括儿童精神病评定量表（CPRS），临床总体印象改善量表（CGI-I），儿童总体评价量表（CGAS）和利培酮副作用清单。结果：患者接受利培酮治疗的时间为1到32个月（7.9 +/- 6.8个月）。在完成研究后，有25名患者（47.2％）继续接受利培酮，而由于副作用（22.6％[N = 12]），父母的选择（18.9％[N = 10]）停药的患者中有28名（52.8％）停药。 ），缺乏疗效（5.7％[N = 3]）和治疗精神病医生的决定（5.7％[N = 3]）。最佳剂量为0.55 +/- 0.2 mg /天。在最后一次观察中发现CPRS（p <.0001）和CGAS（p <.0001）得分有显着改善。根据CPRS得分提高25％和CGI-1得分分别为1或2，将46.8％（N = 22）的受试者视为应答者。行为障碍和情感失调比人际功能对治疗更敏感。与无反应者相比，反应者在更长的时期内接受了更高剂量的药物，并且体重增加更大。无临床症状的催乳素水平升高（65％[37分之24]）和食欲增加（15％[531分之8]）是最常见的副作用。结论：这些发现表明，低剂量的利培酮不仅可以在短期内而且可以在长期内积极影响PDD幼儿的临床结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号